Good day everyone and welcome to the T2 Biosystems Inc. Fourth Quarter and Full-Year 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

It is now my pleasure to turn the floor over to your host, [indiscernible] Investor Relations. Ma'am the floor is yours..

Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products.

Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements including the risks and uncertainties described in T2 Biosystems' Annual Report on Form 10-K filed with the SEC on March 23, 2022, and other filings the company makes with the SEC from time to time.

The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. With that, I would like to turn the call over to Chairman and CEO, John Sperzel.

John?.

Thank you all for joining our fourth quarter and full-year 2022 earnings call. Today, I will discuss our performance in the fourth quarter, the progress we have made across our three corporate priorities, and our outlook for 2023.

I will then turn the call over to John Sprague, our Chief Financial Officer, who will review our fourth quarter and full-year financial results.

Before I provide closing remarks and we open the call for questions and answers, I want to start by recognizing the T2 Biosystems team for achieving a number of sales records and key accomplishments during 2022.

Commercially, we achieved record full-year 2022 Sepsis and related product revenue that is non-COVID product revenue and a record number of full-year Sepsis driven T2Dx instrument contracts. We also ended the year on a high note with record fourth quarter U.S. sepsis test sales.

Operationally, we completed a program to reduce the manufacturing cost of the T2Bacteria panel and the T2Candida panel, and we reduced our operating expenses and headcount. With our new product pipeline, we completed the clinical evaluation for the T2Biothreat Panel, advanced the U.S.

Clinical trial for the T2Resistance Panel and received the LymeX Award and FDA Breakthrough Device designation for our T2Lyme panel. These accomplishments support our mission to fundamentally change the way medicine is practiced through transformative, culture independent diagnostics to improve the lives of patients around the world.

The COVID-⁠19 Pandemic emphasized that rapid diagnosis are essential to understanding the status of the patient before they receive treatment.

In each of our target markets, which now include Sepsis and Lyme disease, we believe our products will enable faster targeted therapy that will lead to improved patient outcomes, reduced costs and lower mortality rates. I'd like to provide background on the opportunity T2 Biosystems is uniquely positioned to address in Sepsis and Lyme disease.

Sepsis presents one of the greatest challenges to healthcare systems worldwide, claiming approximately 11 million lives each year.

In the U.S., Sepsis is the number one cause of hospitalization costing our healthcare system approximately $62 billion annually, the number one cause of death in hospitals, claiming the lives of approximately 270,000 Americans annually, and the number one cause of 30 day hospital readmissions, requiring nearly 20% of Sepsis survivors to be readmitted within 30 days and nearly 40% to be readmitted within 90 days.

These figures should be unacceptable to everyone everywhere. Last month, the Los Angeles Times reported a 46% increase in the number of patients who developed Sepsis while in California hospitals between 2019 and 2021.

The same report highlighted that COVID-⁠19 infection itself also elevates the risk of Sepsis, especially among older adults who are hospitalized, as nearly 40% of severe Sepsis patients who died at California hospitals in 2021 had COVID-⁠19.

The current standard of care for patients at risk of sepsis relies on broad incurred protocols to administer antimicrobial therapy, despite the fact that these protocols are only optimal in approximately one half of cases and can contribute to the growing threat of antimicrobial resistance.

The current standard of care also relies on a positive blood culture to identify the presence of a bloodstream infection, which has two limitations, one, blood culture can take one to five days to turn positive, which can result in delayed targeted treatment.

And two, blood culture is widely known to have poor sensitivity, which can cause false positive or false negative results.

For Sepsis patients, data shows that each hour of delayed targeted antimicrobial treatment can lead to increased mortality risk of up to 8%, demonstrating that rapid detection of Sepsis causing pathogens and antibiotic resistance genes is critical to achieving targeted treatment decisions and improving patient outcomes.

Given our development progress with the T2Lyme Panel, we have expanded our target market to include Lyme disease. Lyme disease is a bacterial infection caused by the Bacteria Borrelia and is considered the most common vector borne illness in the United States. Borrelia burgdorferi is transmitted to humans through the bite of infected ticks. The US.

Centers for Disease Control and Prevention, or CDC noted approximately 476,000 Americans may get Lyme disease each year in the United States. Typical symptoms can include fever, headache, fatigue and skin rash. If left untreated, infection can spread to joints, the heart and the nervous system.

The current CDC recommended serological testing for Lyme disease relies on the presence of antibodies and can only be used accurately four to six weeks after infection, illustrating a significant unmet need for a sensitive diagnostic test to detect early Lyme disease. The initial performance data on our T2Lyme Panel is very encouraging.

We believe the T2Lyme panel will allow clinicians to detect active infections, ensure patients receive appropriate therapy faster, and prevent the negative impact of a delay in delivery of treatment and the overuse of antibiotics.

To create value for our stakeholders, we're focused on three corporate priorities, one, accelerating our sales; two, enhancing our operations; and three, advancing our pipeline. I'll now provide an update on each of those corporate priorities, including our recent progress and our 2023 plans, starting with our first priority accelerating our sales.

Our U.S. go-to-market strategy includes a direct sales force targeting hospitals. We're focused on increasing the adoption of our products with emphasis on increasing sales of our Sepsis test panels and expanding the installed base of our T2Dx instruments, while also solidifying commercial plans for our T2Lyme Panel.

Our commercial team, which includes sales, marketing, medical affairs, service, and support is completely aligned and reports to a single leader. We are focused on educating consumers on the clinical value of our Sepsis products, including leveraging the peer reviewed publications that support the use of T2Candida and T2Bacteria panels.

The team is also focused on expanding the patient selection criteria to increase Sepsis test utilization.

I'm pleased that we're gaining traction in the market, evidenced by our strong finish in 2022, and that our customers are benefiting from the support of our Scientific Advisory Board and our key opinion leaders, or KOLs who serve as references for clinical integration models.

In 2022, we achieved record full-year Sepsis and related product revenue or non-COVID product revenue of $8.4 million, representing growth of 17% compared to 2021, and we achieved record fourth quarter U.S. Sepsis test revenue.

We also achieved record full-year Sepsis driven T2Dx instruments totaling 51 instruments comprised of 27 from the United States and 24 from outside of the United States. Our growing installed base of T2Dx instruments was 181 at the end of 2022, including 106 in the U.S. and 75 internationally.

The expanding adoption of our Sepsis products was evidenced by the sale of a T2Dx instrument to one of the leading U.S. laboratory service providers to be used within one of the providers managed hospital laboratories.

We also sold two T2Dx instruments to one of our existing customers, a leading healthcare system in Pennsylvania, to support their expanding Sepsis testing needs. We're pleased to continue the trend of additional instrument orders from the same account, which we believe validates the clinical and economic value of our technology.

Outside of the U.S., we believe there is a large market opportunity for our instruments and Sepsis test panels. Our international go-to-market strategy involves partnering with a network of exclusive distributors that sell and support our products in target countries.

During 2022, we sold 24 T2Dx instruments internationally, and we expanded our commercial footprint by adding distributors in South Africa and countries in Scandinavian and Baltic regions.

In 2023, we plan to further expand our distribution networks to drive adoption and introduce our products into additional high value markets, including additional countries in Europe, Middle East, Latin America, and Asia-Pacific. Looking Ahead in 2023, we plan to focus our commercial efforts in areas where we can generate more profitable revenue.

Our top priority will be increasing the use of our Sepsis test panels with existing hospital customers.

The medical affairs team is integrated with our commercial team and equipped with the data, KOL, Scientific Advisory Board and reference account support to make extremely compelling clinical and economic cases to drive broader patient selection and increased utilization.

We've been successfully driving utilization in small to midsize hospitals where Sepsis management protocols have the ability to be updated more quickly, and we will continue to target these hospitals in 2023. We believe that the Sepsis treatment gap has widened, as shown by the management of COVID-⁠19 patients throughout the pandemic.

And we understand our customers that already have T2Dx instruments are prepared to address the challenges posed by Sepsis. Given our commercial focus in 2023, we believe the most accurate measure of our success will be our ability to generate product revenues, and we are choosing to provide guidance accordingly.

We expect total 2023 Sepsis and related product revenue of $11 million to $13 million, representing growth of 31% to 55% compared to the $8.4 million we achieved in 2022. This guidance assumes no revenue from the sale of our T2SARS-CoV-2 Panel.

We expect growth to be driven by increased sales of our Sepsis test panels, supported by sales of T2Dx instruments. Potential FDA clearance of the T2Resistance panel would represent a meaningful catalyst for product revenue, both as a standalone product and due to its expected positive impact on the adoption of the T2Bacteria panel.

Moving to our second priority, enhancing our operations. Given the current economic environment, operating efficiently is critical to our success. During the second quarter of 2022, we reduced our overall cost structure, including reductions in headcount, which now stands at 160 employees, and operating expenses.

As part of the headcount reductions, we eliminated the position of Chief Operations Officer and as a result, our Vice President of Operations and Vice President of Quality Assurance and Regulatory Affairs are now reporting directly to me.

During 2022, we made process improvements to the T2Bacteria and T2Candida panels to reduce manufacturing costs and gain manufacturing efficiencies. We believe these improvements will contribute to improved product gross margins, which we expect to begin positively impacting our financials in 2023.

In recent weeks, we've experienced what we believe is a raw material issue that was identified during routine internal quality inspection. This has limited our ability to manufacture sufficient volume of cartridges to meet current customer demand.

As this was identified during in-process inspection, the product that was shipped to customers and distributors was not affected. As a result, while customer demand remains strong, we currently have a backorder for some of our test panels, which we hope to ship by the end of March.

From a facilities perspective, we believe that we will continue to meet our current manufacturing needs with our operations at our Lexington and Wilmington, Massachusetts facilities.

As previously reported, the company entered into a lease agreement in September 2021 to lease a facility in Billerica, Massachusetts, in order to consolidate our office, laboratory and commercial manufacturing spaces.

In January 2023, the landlord terminated the lease due to the company's alleged breach of the agreement, and the landlord subsequently filed a complaint with the Massachusetts Superior Court.

The company disagrees with the Landlord's allegations and in March 2023 filed a response to the landlord's complaint and a counterclaim alleging that in fact the landlord breached its obligations under the contract and unlawfully drew on the security deposit.

In addition to breaching its covenants of good faith and fair dealing, making fraudulent misrepresentations, and engaging in deceptive and unfair trade practices. Finally, during the first quarter of 2023, we strengthened our balance sheet by raising $12 million in gross proceeds.

We will continue to be disciplined with our operating expenses and execute on our revenue growth plan with existing commercial resources to increase our operating leverage and extend our cash runway.

Moving to our third priority, advancing our pipeline, we're advancing the development of multiple new products that leverage both our technology platform and our scientific expertise. Our product pipeline is supported by a milestone based product development contract awarded to us by the U.S.

Biomedical Advanced Research Development Authority, or BARDA which is valued at up to $62 million if all options are exercised. Our new product pipeline is focused on two goals one, developing new tests to expand the test menu on the T2Dx instrument, and two, developing a next generation instrument and comprehensive sepsis test panel.

In the near-term, we're developing five new tests aimed at expanding the menu on our FDA cleared T2Dx instrument, each representing a differentiated solution to rapidly identify harmful pathogens and potentially allow clinicians to achieve faster targeted therapy.

The T2Biothreat Panel is a direct from blood molecular diagnostic test designed to simultaneously detect six Biothreat pathogens identified as threats by the CDC, including the organisms that cause anthrax, tularemia, glanders, melioidosis, plague and typhus.

If not treated promptly, infections with these pathogens can result in mortality rates of 40% to 90%. In the event of a public health emergency involving Biothreat pathogens, rapid and accurate diagnostic testing is expected to play a central role in minimizing health and economic impact. We have recently completed the U.S.

clinical evaluation and announced that the results demonstrated very high sensitivity and specificity across all six Biothreat targets exceeding target performance requirements. We are very pleased with the results and we have shifted our focus to filing the submission with the FDA for U.S.

regulatory clearance and subsequently pursuing commercial sales with the goal of protecting Americans from the threat of deliberate or naturally occurring outbreaks of Biothreat pathogens. The T2Biothreat Panel has been funded under our contract with BARDA.

The T2Resistance Panel is a direct from blood and molecular diagnostic test designed to simultaneously detect 13 antibiotic resistance genes known to cause antibiotic resistant infections in just three to five hours without the need to wait days for a positive blood culture.

The T2Resistance Panel, which is marketed and sold in Europe under CE Mark detects resistance genes that may confer resistance to common antimicrobials such as carbapenems, methicillin and vancomycin. We expect to complete patient enrollment of approximately 1,500 patients in our ongoing U.S.

clinical trial during the second quarter and plan to file our submission to the FDA upon completion of the study. As a reminder, the T2Resistance Panel was granted Breakthrough Device designation by the FDA, which provides for a prioritized review process upon submission. The T2Resistance Panel has been funded under our contract with BARDA.

The T2Lyme Panel is a direct from blood molecular diagnostic test designed to detect Borrelia burgdorferi, the bacteria that is the major cause of Lyme disease in the United States. The T2Lyme Panel is intended to test individuals with signs and symptoms of Lyme disease and aid in the diagnosis of early Lyme disease.

We believe the T2Lyme Panel will provide a significant advantage over the currently recommended serological testing that requires the presence of antibodies which can take the body four to six weeks to create post infection.

During 2022, the FDA granted Breakthrough Device designation for the T2Lyme Panel allowing for a prioritized review process upon submission to the FDA and we received a patent from the U.S. Patent and Trademark Office covering the T2Lyme Panel.

In addition, we announced that the T2Lyme Panel was a winner in the Lyme Innovation Accelerator, also known as LymeX, a partnership between the U.S. Department of Health and Human Service and the Steven & Alexandra Cohen Foundation, the largest public private partnership for Lyme disease that includes up to $10 million in funding.

Our plan is to commence commercialization of the T2Lyme Panel as a laboratory developed test and subsequently commence a U.S. clinical trial to support submission for FDA clearance. Candida Auris is a direct from blood molecular diagnostic test that we plan to add to the T2Candida panel to expand the number of pathogens detected on the test panel.

Candida Auris is a multidrug resistant pathogen recognized by the CDC as a serious global health threat. According to CDC, Candida Auris is difficult to identify with standard laboratory methods which can lead to inappropriate treatment and some strains are resistant to all three available classes of antifungals.

We believe adding Candida Auris to our existing T2Candida panel will provide a significant time advantage compared to other blood culture based methods. Acinetobacter baumannii is a direct from blood molecular diagnostic test that we plan to add to the T2Bacteria panel to expand the number of pathogens detected on the test panel.

Acinetobacter baumannii can cause bloodstream infections, especially in critically ill patients, which can range from benign transit bacteremia to septic shock and has been reported to have crude ICU mortality rate of 34% to 43%.

Acinetobacter infections rarely occur outside of healthcare settings in the United States and can disproportionately impact those with weakened immune systems, chronic lung disease or diabetes.

Acinetobacter can be resistant to many antibiotics, including carbapenems, highlighting the importance of rapid detection and targeted antimicrobial treatment. Longer-term, we're developing our next generation Sepsis products, including a new instrument and a comprehensive Sepsis test panel.

The next generation instrument is designed to be fully automated and random access, similar to our T2Dx instrument, but incorporates faster turnaround times and the ability to detect an increased number of targets from a single whole blood sample.

The comprehensive Sepsis Test Panel is a direct from blood test designed to detect greater than 95% of all bloodstream infections caused by Bacterial and Candida species and antibiotic resistance genes identified as threats by the CDC in a single test with a time to result of approximately three hours.

The next generation instrument and comprehensive Sepsis panel have been funded under our contract with BARDA. We're currently operating in Option 3 of the BARDA contract, having successfully met all development milestones under the base phase, Option 1, Option 2A and Option 2B.

We anticipate filing a no cost extension with BARDA under Option 3 to allow time for the completion of the T2Resistance U.S. clinical trial. Further funding from BARDA may resume following the completion of Option 3 and BARDA's exercise of Option 4. Given the uncertain timing, we are not providing guidance on 2023 BARDA revenue at this time.

With that, I'll turn the call over to John Sprague to provide a detailed update of our fourth quarter financial results and our financial outlook for 2023.

John?.

Thank you, John. Total revenue for the fourth quarter of 2022 was $5.5 million, a decrease of 21% compared to the prior-year period. Product revenue was $2.2 million, a decrease of 45% compared to the prior-year period, driven by the expected 89% decline in COVID-⁠19 test sales and partially offset by increased Sepsis test sales.

Research contribution revenues were $3.3 million, an increase of 10% compared to the prior-year period driven by the timing of enrollments in the T2Resistance clinical trial. Product costs for the fourth quarter of 2022 were $3.8 million, a decrease of 30% compared to the prior-year period driven by decreased COVID-⁠19 test sales.

Research and development expenses were $4.9 million, a 9% decrease compared to the prior-year period driven by decreased development expenses during the clinical trial phases of the BARDA contract. Selling, general and administrative expenses were $6.7 million, an increase of 2% compared to the prior-year period, driven by increased selling activity.

Net loss for the fourth quarter of 2022 was $10.4 million, a $1.41 per share compared to a net loss of $12.1 million, $3.65 per share for the prior-year period. Cash equivalents and restricted cash were $11.9 million.

As of December 31, 2022, we raised $2.2 million through ATM sales in the fourth quarter of 2022, and in February 2023, we raised $12 million through common stock in warrant sale. We redeemed the Series A preferred stock in October 2022, and there are no longer any preferred shares outstanding.

We remain in compliance with the CRG loan agreement covenants. For guidance, we expect 2023 total Sepsis and related product revenue of $11 million to $13 million, representing growth of 31% to 55% compared to $8.4 million in 2022. Given our focus on product revenue, we are not providing guidance on research and contribution revenue.

Thank you, and back to John Sperzel for closing remarks..

Thank you, John. In 2022, T2 Biosystems achieved record full-year Sepsis and related product revenue globally, record fourth quarter Sepsis test revenue in the U.S. and record full-year sepsis driven T2Dx instrument contracts. We're pleased with our growing commercial momentum in the market.

Operationally, we've taken steps to reduce product cost and operating expenses, which we believe put us on a path to improve profitability and reduce cash burn. Our product pipeline is advancing. Through progress with our clinical trials in the U.S. for the T2Resistance Panel and with the completion of the T2Biothreat Panel trial.

Additionally, we received FDA Breakthrough device designation and the LymeX Award for our T2Lyme panel. As we look ahead to 2023, we are well positioned to continue to advance our three corporate priorities, including accelerating our sales, enhancing our operations, and advancing our pipeline to support long-term growth and sustained value creation.

I'd like to turn the call back over to the operator to open the line for questions.

Operator?.

Certainly. At this time, we'll be conducting a question-and-answer session. [Operator Instructions]. Your first question is coming from Mark Massaro from BTIG. Your line is live..

Hey, guys. Thank you for taking the questions. I appreciate the extensive prepared remarks, John, maybe just a little more clarity as to why you're not breaking out or sorry, why you're not guiding for research revenue. I think I heard you talk about Option 3 and Option 4 with BARDA, just kind of confirming that seems like it may be a timing issue.

But obviously your plans with BARDA remain on, right? So is it fair for us to expect product -- excuse me, research revenue in 2023? Or is this really you looking at the clock and saying maybe research revenue won't come in this year due to timing?.

Hi, Mark. Thanks for the question. So, our overall BARDA contract, which we received in late 2019 was up to $62 million. We've received about half of that to date through the end of 2022, which included the base phase, Option 1, Option 2A and Option 2B, and part of Option 3.

As I mentioned, we plan on filing for a no cost extension, which will give us additional time to complete the T2Resistance clinical trial, that is part of option three. We certainly anticipate negotiating with BARDA over Option 4. The timing is a little bit difficult to predict given the extended period for the T2Resistance clinical trial.

We're obviously hopeful about receiving funding in 2023, but that's certainly at BARDA's discretion. So for that reason, we're not guiding..

Okay, that's helpful. I understand that, obviously focusing on existing customers probably is a higher ROI and probably certainly lower cost in nature. Can you just give us, I should say, new customer acquisition costs would be lower. Can you just give us a sense for the size of your commercial team, just want to mind an update there.

Just making sure you have adequate boots on the ground..

Mark, you're spot on with your assessment of why we're focusing on existing customers and why we're prioritizing increased Sepsis test sales over broadening our installed base of instruments. It's a better use of capital and obviously lowers our customer acquisition costs. We divided the geography into 20 sales territories.

We have thinned some of our salespeople who quite frankly weren't performing. And I believe we have 12 of those territories filled. The open territories are being filled by adjacent sales reps. And as I said in the prepared remarks, we are planning to go to battle, so to speak with the team that we have throughout 2023 to limit our cast usage..

Yes, that makes sense.

Maybe one last question for me, I may have missed it, but did you provide an outlook for new instrument placements for the year? How should we think about that?.

We did not..

Okay, I appreciate the color. Thanks..

Thank you, Mark..

Thank you. Your next question is coming from Ben Haynor from Alliance Global Partners. Your line is live..

Good afternoon, gentlemen. Thanks for taking the questions.

First off for me, on T2Lyme, you mentioned, if I heard you correctly, that you're starting out marketing that as an LDT, what is the right way to think about when that starts being commercialized, when we can see revenue from that and any other color that you have on commercialization there?.

Yes, so I think the first point, Ben, is that we have not begun commercializing as an LDT yet. We intend to do that during 2023. We know that typically the Lyme season starts in June, although with the way the weather patterns have been, particularly in the Eastern part of the United States, in the early part of 2023, the Lyme season may be expanded.

So you can think about our potential to commercialize in the second half of the year. And we are in discussion with potential partners on the best way to go about that commercialization. We have not provided any revenue in our guidance for T2Lyme panel. So that represents upside..

Okay, so that was going to be my next question, and the plan is there to partner basically -- certainly partner rather than maybe open your own or acquire lab to do it yourselves?.

Both of those options are on the table, and we're exploring them both simultaneously..

Okay, got it. So stay tuned there. Excellent.

And then on kind of the manufacturing cost take out that you've had, can you give us a sense of what gross margin could look like on the consumables exiting the year, if you do achieve your guidance range?.

John Sprague, would you like to take that, please?.

Yes, so I mean, we're still -- we still have very strong direct margins, Ben. So in the 70% to 80% range and then volume plus the operational efficiencies are reducing the overhead impact on all that. So that's really the way we think about margins..

Okay, so 70%, 80% marginal gross margin and just cover the fixed cost beyond that..

Exactly. And the fixed cost at this point is steady. We've got plenty of capacity for both instruments and reagent tests..

Got it. I think that's all I had for the moment. I'll jump back in queue..

Thank you, Ben..

Thank you..

Thank you. [Operator Instructions] Your next question is coming from Kyle Mikson from Canaccord. Your line is live..

Hey, guys. Thanks for taking the questions. Congrats on the record results for the quarter and for the year. Just on the guidance, I guess John wanted to give you the opportunity to talk about the lack of placement guidance, I guess, and why that is less visible to you, given the backlog that you kind of mentioned, I think.

And then also for '23, do you think that the product revenue is not going to be more skewed towards consumables revenue this year or instruments? Thanks..

Thank you for the question, Kyle. So our revenue, our Sepsis and related product revenue in 2023, we expect to be driven primarily by test cartridges, T2Bacteria, T2Candida, T2Resistance, certainly that will be increased if we're successful in getting T2Resistance in front of and cleared by the FDA.

As far as instrument guidance or lack of instrument guidance, we just chose to focus our entire organization around driving Sepsis and related product revenue. That includes the corporate incentives. It includes the sales rep compensation. And so, likewise, we're making our guidance in line with that..

Okay. All right, that's fair. Thanks for that. And just one more on the guidance, I think you mentioned a raw material issue recently. You think that's going to get resolved quickly, and then you want to ship and recognize revenue on all the back orders by the end of March.

So the guidance here is that predicated based on that assumption? And then what happens if that kind of trickles into the second quarter? Does that delay further shipments and stuff like later in the year and then that kind of affects the guide as well.

Just kind of thinking about that?.

Sure. As a reminder, we have a highly sensitive platform, so any agent that might be in a raw material can impact the quality of the product. As I mentioned in the prepared remarks, we caught this in our Internal Quality Inspection. So none of that product got to customers. We anticipate resolving the back order by the end of March.

If that doesn't occur, then some of that revenue we would expect to spill into the second quarter..

Okay, got you. And on the research and contribution revenue, sorry to keep going over the financials here, but it's interesting to breakout here. So I heard what you were saying about the extension to allow for the time for the Resistance Panel, and that might kind of allow you to complete Option 3 and then I guess Option 4 thereafter.

I mean, what would happen if you're denied, I guess that extension like what would that do for the BARDA contract as a whole? And would you even be allowed over time to get to Option 4, I mean just how do we, if we are talking the worst case scenario there, I guess?.

Sure. Between 2019, I think the Fall of 2019 when the BARDA contract was granted and the end of 2022, two no cost extensions had already been filed, one at the request of BARDA, one at the request of T2, in the case of BARDA, they weren't ready to fund the next option at that time.

And in our case, we needed a little bit more time to generate some data. In both cases, all of the milestones were met according to the statement of work in the contract. So I think it's very unlikely that BARDA would not accept our no cost extension request. And we've already had those discussions with them..

Okay, perfect. Thanks for that. And I guess what are some of the other sources of research and contribution revenue outside of BARDA, I don't think that's 100% of that revenue line. So just maybe remind us of other sources there just so we have some cushion there, I guess..

There was the initial $100,000 that we received as part of the LymeX Award. As I mentioned in the earlier remarks, the Steven & Alexandra Cohen Foundation have put up to $10 million in funding. There were 62, I believe companies initially involved, 10 were chosen. Those 10 split a million dollars.

My understanding is in Phase 2, by the end of Phase 2, that number of companies is going to be whittled down to three or four, which have the potential to split the remaining $9 million in some way, shape or form, so that revenue would be in addition or outside of the BARDA revenue in research and contribution.

John Sprague, is there anything else there?.

No, that captured it..

Okay, thanks, guys. And then, John Sperzel, any milestones for the NextGen products this year, the instrument of the comprehensive panel, I mean it is really, it is exciting, we've been talking about it for, like, years.

I feel like, is there going to be any kind of milestone this year that we can look forward to?.

Very exciting. Obviously, we are hopeful that those will be discussed under Option 4 of the BARDA contract. In fact, Option 4, 5 and 6, which are the remaining options under that contract, because we expect to complete everything for T2Biothreat and T2Resistance under Option 3.

So the only thing remaining under the BARDA funding would be for NextGen instrument and the comprehensive sepsis panel. We totally agree. It's super exciting..

Got it. Okay. That's right. That's right. And last one for me for John Sprague on cash. Good to see, I guess like the influx of cash in the first quarter.

Any sense for burn maybe for the first quarter or for the year, maybe compared to 2022, just curious if you can kind of talk through that and I guess, like, how much of a headwind to top line growth is that and if you could spend more this year, could product revenue growth be over 50% or just more robust this year, I guess. Thanks..

Sure. So we're seeing burns coming down below that historic 11 million to 12 million. So it should be in the $9 million to $10 million range going forward, both as we've controlled costs and headcount as well as we start leveraging Sepsis sales.

I think in terms of our spend, spending more isn't necessarily going to get us new customers at this juncture. We've got a robust commercial team and the goal is to keep it robust at the present levels. So I don't think we need to double down to increase the top line at this point..

And Kyle, I'll just add to that. At the top end of our guide in Sepsis and related product revenue, which is our core business. The $13 Million would represent a 55% increase over what we achieved In 2022. And keep in mind, in that guidance, there is no T2Lyme and there is also no T2Biothreat..

Okay.

And there's no COVID too, right in that product revenue guidance?.

That's correct..

Perfect. All right, fantastic. Thanks so much, guys. I appreciate it..

Thank you..

Thank you, Kyle..

Thank you. That concludes our Q&A session. I would now hand the conference back to John Sperzel, Chairman and CEO for closing remarks. Please go ahead..

Thank you all for joining our fourth quarter 2022 and full-year 2022 earnings call. We appreciate your support, and we look forward to our Q1 earnings call. Thank you very much. Have a great day..

Thank you, everyone. This concludes today's event. You may disconnect at this time and have a wonderful day. Thank you for your participation..